LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences:
22nd Annual Craig-Hallum Institutional Investor Conference
1x1 Meetings
Date: Wednesday, May 28, 2025
Location: Minneapolis, MN
45th Annual William Blair Growth Stock Conference
Presentation and 1x1 Meetings
Date and Time: Wednesday, June 4, 2025 at 9:20 AM CT
Location: Chicago, IL
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-720-925-9285
Investors:
Chris Brinzey
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-339-970-2843
Last Trade: | US$0.31 |
Daily Change: | 0.0036 1.18 |
Daily Volume: | 456,348 |
Market Cap: | US$45.290M |
May 22, 2025 May 15, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load